0001375151-18-000074.txt : 20181009
0001375151-18-000074.hdr.sgml : 20181009
20181009173748
ACCESSION NUMBER: 0001375151-18-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181004
FILED AS OF DATE: 20181009
DATE AS OF CHANGE: 20181009
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farfel Gail M
CENTRAL INDEX KEY: 0001614780
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34962
FILM NUMBER: 181114472
MAIL ADDRESS:
STREET 1: 142 TEMPLE STREET
STREET 2: SUITE 205
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZOGENIX, INC.
CENTRAL INDEX KEY: 0001375151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205300780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET, #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: (510) 550-8300
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET, #455
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: ZOGENIX INC
DATE OF NAME CHANGE: 20060911
4
1
wf-form4_153912105220309.xml
FORM 4
X0306
4
2018-10-04
0
0001375151
ZOGENIX, INC.
ZGNX
0001614780
Farfel Gail M
C/O ZOGENIX, INC.
5858 HORTON STREET, SUITE 455
EMERYVILLE
CA
94608
0
1
0
0
EVP/Chief Development Officer
Common Stock
2018-10-04
4
M
0
6961
13.96
A
14104
D
Common Stock
2018-10-04
4
S
0
2100
42.9224
D
12004
D
Common Stock
2018-10-04
4
S
0
2900
43.1123
D
9104
D
Common Stock
2018-10-04
4
S
0
1961
43.7356
D
7143
D
Stock Option (Right to Buy)
13.96
2018-10-04
4
M
0
6961
13.96
D
2025-06-30
Common Stock
6961.0
30289
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $42.65 to $43.03, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $43.04 to $43.19, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price.These shares were sold in multiple transactions at prices ranging from $43.22 to $44.70, inclusive.The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option was granted on July 1, 2015, which is the vesting commencement date. One-fourth of the shares subject to the option will vest on the first anniversary of the vesting commencement date, and the remaining shares subject to the option shall vest in thirty-six equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment with the Company on each vesting date.
/s/ Thomas Doyle, Attorney-in-fact for Gail Farfel
2018-10-09